Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aprovel irbesartan regulatory update

EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include a contraindication for patients with diabetes or moderate to severe renal impairment

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE